TKI-treated Patients With CML May Have Increased Risk of Vascular Events

Share this content:
Patients with CML treated with a TKI may have an increased risk of vascular events.
Patients with CML treated with a TKI may have an increased risk of vascular events.

Patients with chronic myeloid leukemia (CML) treated with a first- or second-generation tyrosine kinase inhibitor (TKI) may have an increased risk of arterial and venous vascular events, according to a study published in the Annals of Internal Medicine.1

Although the introduction of TKIs has dramatically improved survival and life expectancy of patients with CML, continuous administration of these agents may induce long-term toxicities. Researchers examined the incidence of vascular events in patients with CML treated with the first generation TKI, imatinib, and second-generation TKIs, nilotinib and dasatinib.

Of 896 enrolled patients with CML in chronic phase, 94.4% had documented treatment with a TKI. Patients were followed for a median of 4.2 years; results showed that 54 arterial (relative risk, 1.5; 95% CI, 1.1-2.1) and 20 venous events (relative risk, 2.0; 95% CI, 1.2-3.3) were reported in the cohort of patients with CML.

Researchers also found that patients treated with second-generation TKIs had a higher rate of myocardial infarction, in contrast with those who received imatinib. More data are necessary, however, to determine whether the risk of myocardial infarction increases with use of nilotinib and dasatinib.

RELATED: Treatment-free Remission Attempts Feasible in Patients Treated With Second-line Nilotinib for CML-CP

Twenty-six of the 31 patients treated with a TKI who had a mydocardial infarction were diagnosed with at least 1 cardiac risk factor beforehand.

This study was limited by the inclusion of patients exposed to multiple TKIs. Data on second- and third-generation TKI were limited.

Reference

  1. Dahlen T, Edgren G, Lambe M, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016 Jun 14. doi: 10.7326/M15-2306 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters